We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Gaboxadol in Primary Insomnia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00209963
First Posted: September 21, 2005
Last Update Posted: March 30, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
H. Lundbeck A/S
September 13, 2005
September 21, 2005
March 30, 2007
June 2003
Not Provided
Long-term safety in gaboxadol.
Not Provided
Complete list of historical versions of study NCT00209963 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of Gaboxadol in Primary Insomnia
A Prospective Randomised Double-Blind Parallel-Group Placebo-Controlled Study of Gaboxadol in Primary Insomnia
To evaluate the safety and tolerability of gaboxadol in primary insomnia.
To obtain long-term safety and tolerability data with gaboxadol.
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Primary Insomnia
Drug: Gaboxadol
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
600
March 2005
Not Provided

Inclusion Criteria:

  • patients with Primary insomnia
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00209963
99784
No
Not Provided
Not Provided
Not Provided
H. Lundbeck A/S
Not Provided
Study Director: Please contact: Annelies van der Hammen Legters H. Lundbeck A/S
H. Lundbeck A/S
March 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP